Clinical Trial

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay in the body after dosing? Researchers will compare ATTO-3712 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-3712 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-01; most recent amendment 2026-05-27.
Status change: Recruiting → Active, Not Recruiting 2026-05-27
Status change: Not Yet Recruiting → Recruiting 2025-11-20
Trial Details
NCT Number NCT07205081
Lead Sponsor Attovia Therapeutics Inc
Conditions Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
Enrollment 72 participants
Start Date 2025-10-22
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-28